

Prior Authorization Review Panel

CHC-MCO Policy Submission

A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review.

Plan: PA Health & Wellness	Submission Date: N/A	
Policy Number: PHW.PDL.506	Effective Date: 01/05/2021 Revision Date: 10/2021	
Policy Name: Hematopoietic Mixtures		
Type of Submission – <u>Check all that apply</u> :		
 □ New Policy □ Revised Policy* ✓ Annual Review - No Revisions ✓ Statewide PDL - Select this box when submitting policies when submitting policies for drug classes included on the Statewide on the Statewide PDL - Select for drug classes included on the State		
*All revisions to the policy <u>must</u> be highlighted using track changes throughout the document.		
Please provide any changes or clarifying information for the policy below:		
Q1 2022 annual review: no changes.		
Name of Authorized Individual (Please type or print):	Signature of Authorized Individual:	
Venkateswara R. Davuluri, MD	- Raulun	



Clinical Policy: Hematopoietic Mixtures

Reference Number: PHW.PDL.506 Effective Date: 01/05/2021 Last Review Date: 10/2021

Policy/Criteria

Revision Log

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with PA Health and Wellness[®] that Hematopoietic Mixtures are **medically necessary** when the following criteria are met:

I. <u>Requirements for Prior Authorization of Hematopoietic Mixtures</u>

A. Prescriptions That Require Prior Authorization

Prescriptions for Hematopoietic Mixtures that meet any of the following conditions must be prior authorized:

- 1. A non-preferred Hematopoietic Mixture. See the Preferred Drug List (PDL) for the list of preferred Hematopoietic Mixtures at: <u>https://papdl.com/preferred-drug-list</u>.
- 2. A Hematopoietic Mixture with a prescribed quantity that exceeds the quantity limit.

B. Review of Documentation for Medical Necessity

In evaluating a request for prior authorization of a prescription for a Hematopoietic Mixture, the determination of whether the requested prescription is medically necessary will take into account the whether the beneficiary:

- 1. For a non-preferred Hematopoietic Mixture, has a history of therapeutic failure, contraindication, or intolerance to the preferred Hematopoietic Mixtures; **AND**
- 2. If a prescription for a Hematopoietic Mixture is for a quantity that exceeds the quantity limit, the determination of whether the prescription is medically necessary will also take into account the guidelines set forth in PA.CP.PMN.59 Quantity Limit Override.

NOTE: If the beneficiary does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary, the request for prior authorization will be approved.

C. Clinical Review Process



Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above to assess the medical necessity of a prescription for a Hematopoietic Mixture. If the guidelines in Section B. are met, the reviewer will prior authorize the prescription. If the guidelines are not met the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary.

D. Approval Duration: 12 months

Reviews, Revisions, and Approvals	Date
Q1 2021: policy created according to DHS effective 01/05/2021	11/2020
Q1 2022 annual review: no changes.	10/2021